Toward a molecular classification of the gliomas: histopathology, molecular genetics, and gene expression profiling.
As many as 100,000 new cases of brain tumor are diagnosed each year in the United States. About half of these are primary gliomas and the remaining half are metastatic tumors and non-glial primary tumors. Currently, gliomas are classified based on phenotypic characteristics. Recent progress in the elucidation of genetic alterations found in gliomas have raised the exciting possibility of using genetic and molecular analyses to resolve some of the problematic issues currently associated with the histological approach to glioma classification. Recently, immunohistochemical studies using novel proliferation markers have significantly advanced the assessment of tumor growth potential and the grading criteria of some tumor subtypes. Preliminary studies using cDNA array technologies suggest that the profiling of gene expression patterns may provide a novel and meaningful approach to glioma classification and subclassification. Furthermore, cDNA array technologies may also be used to identify candidate genes involved in glioma tumor development, invasion, and progression. This review summarizes current glioma classification schemes that are based on histopathological characteristics and discusses the potential for using cDNA array technology in the molecular classification of gliomas.
Caskey
L S
LS
Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Fuller
G N
GN
Bruner
J M
JM
Yung
W K
WK
Sawaya
R E
RE
Holland
E C
EC
Zhang
W
W
D001932:Brain Neoplasms / Q000145:classification* / Q000235:genetics / Q000473:pathology; D020869:Gene Expression Profiling; D005910:Glioma / Q000145:classification* / Q000235:genetics / Q000473:pathology; D006801:Humans